<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372084</url>
  </required_header>
  <id_info>
    <org_study_id>CLCI699C2103</org_study_id>
    <nct_id>NCT02372084</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function</brief_title>
  <official_title>A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of Osilodrostat (LCI699) in Subjects With Impaired Hepatic Function Compared to Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in
      subjects with mild, moderate and severe hepatic impairment compared with subjects with normal
      hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2015</start_date>
  <completion_date type="Actual">May 19, 2016</completion_date>
  <primary_completion_date type="Actual">May 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of a single dose of 30 mg osilodrostat: AUClast</measure>
    <time_frame>Predose (Day 0) , and at timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of a single dose of 30 mg osilodrostat: AUCinf</measure>
    <time_frame>Predose (Day 0) , and at imepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of a single dose of 30 mg osilodrostat: Cmax</measure>
    <time_frame>Predose (Day 0) , and at timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of a single dose of 30 mg osilodrostat: T1/2</measure>
    <time_frame>Predose (Day 0) , and at timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of a single dose of 30 mg osilodrostat: CL/F</measure>
    <time_frame>Predose (Day 0) , and at timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of a single dose of 30 mg osilodrostat: Vz/F</measure>
    <time_frame>Predose (Day 0) , and timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To assess the influence of hepatic impairment on the pharmacokinetics (PK) of LCI699i in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship between PK parameters (Cmax and AUC) and baseline hepatic function parameters namely; total bilirubin, albumin, INR (or prothrombin, if INR unavailable)</measure>
    <time_frame>Predose ( Day 0) and at timepoints 0.5, 1, 1.5, 2, 3,4, 6, 8, 12, 24, 36, 48, 72, 96 hours post dose.</time_frame>
    <description>To evaluate the relationship between hepatic function parameters and pharmacokinetics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Pre-treatment, during treatment (Day 1) and 30 days post treatment.</time_frame>
    <description>This will be assessed using laboratory abnormalities, ECG and vital sign assessments of a single 30 mg dose of LCI699</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>osilodrostat (LCI699)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osilodrostat</intervention_name>
    <arm_group_label>osilodrostat (LCI699)</arm_group_label>
    <other_name>LCI699</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥50 kg and BMI between 18-38kg/m2.

          -  Stable liver cirrhosis and evidence of hepatic impairment. ‐Free of significant
             medical disorders unrelated to underlying hepatic impairment

        Exclusion Criteria:

          -  History of any surgical or medical condition which might significantly alter the
             absorption, distribution, metabolism or excretion of drugs

          -  Subjects with ongoing alcohol or drug abuse

          -  Symptoms or history of encephalopathy (Grade 2 or above)

          -  History or presence of liver disease or liver injury (healthy volunteers only)

          -  History or presence of impaired renal function

          -  Clinical evidence of severe ascites.

          -  Total Bilirubin &gt; 6 mg/dL,

               -  Subjects with a serum free cortisol test results that is below the lower limit of
                  normal (based on central laboratory) during the screening period

               -  Concomitant use of a drug that is a strong inducer of the CYP3A4/5 pathway

        Other protocol-defined inclusion/exclusion criteria may apply -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami / Clinical Research Services, Inc. Boynton Beach</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment,</keyword>
  <keyword>osilodrostat,</keyword>
  <keyword>LCI699</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

